Nā Metric Proteoform no ka Hoʻohālikelike Peptide: Ma waho aʻe o ke Kaʻina Maʻemaʻe

Pane wikiwiki

Hōʻike nā Proteoforms i nā ʻano molekala e puka mai ana mai kahi gene ma o ka hoʻololi ʻana o ke kaʻina, ka hana a me ka hoʻololi covalent. ʻO ka hui noncovalent a me ka conformatio…

He aha nā ʻāpana Proteoform no ke ʻano o ka peptide e ana maoli

Kūʻai nui ʻo Peptide P Nā Peptides Nui Mai ka proteomic ka huaʻōlelo. I ka manawa a Smith, ʻO Kelleher a me ka Consortium for Top-Down Proteomics i hāpai i ka huaʻōlelo, ua wehewehe lākou a proteoform e like me nā ʻano molekala like ʻole a pau e loaʻa ai ka huahana protein o kahi gene hoʻokahi, me nā loli mai ka hoʻololi genetic, hoʻololi ʻē aʻe ma hope o ka unuhi ʻana. No kahi peptide synthetic a recombinant paha, ʻO ia wehewehe ka hana pono o ka koi ʻana i ka nui e wehewehe ʻia ma ke ʻano he heluna ma mua o kahi laina kikokikona.

Nā Metric Proteoform no ka Hoʻohālikelike Peptide: Ma waho aʻe o ke Kaʻina Maʻemaʻe

ʻO ka hōʻailona maopopo loa o ka neʻe ʻana o kēia paʻi ʻana mai ka noiʻi ʻana i ka hoʻolālā a 2026 ʻO ka pepa JACS e wehewehe ana i kahi Pūnaehana Metrics Explicit Proteoform (PrEMS), kahi e hoʻopili ai i nā hoʻololi ʻana o nā kiko i nā enzymes photocyclase artificial i ka catalytic enantioselectivity ma o nā hiʻohiʻona.. Aia nā wehewehe kikoʻī o ka pepa i loko o ka ʻatikala a me kāna ʻikepili i waiho ʻia; ʻO ka mea nui ma ʻaneʻi ʻo ia ka neʻe ʻana, ka mālama ʻana i nā proteoform like ʻole e like me nā ʻano hoʻolālā hiki ke ana ʻia ma mua o ka walaʻau hope.

ʻAno

Nīnau ia pane

ʻano maʻamau

ʻIke a me ke kaʻina

ʻO ka hale mua ka mea a mākou i kauoha ai?

MS paʻa, LC-MS/MS peptide palapala palapala

Maʻemaʻe kemika

ʻEhia ka nui o ka hōʻailona detector ka piko kiʻekiʻe?

RP-HPLC-UV

maʻiʻo ʻupena

ʻEhia ka nui o ka peptide i loko o ka vial?

Ka nānā ʻana i ka ʻakika amino, qNMR, kaulike lehulehu

Hōʻike hoʻololi

ʻO wai nā PTM i kēia manawa, a ma hea?

LC-MS/MS peptide palapala palapala, paʻa MS

Hōʻike ʻoki ʻoki

ʻO ka hope hea i nalowale, a ma ka hapa hea?

MS paʻa, luna-lalo a i ʻole MS maoli

Ka nui a me ka hoʻopaʻa ʻana heterogeneity

Aia nā hui, nā ʻāpana a i ʻole nā ​​ʻokoʻa uku?

SEK, CE-SDS, EX

Conformationally Peptideprice ʻano pili pili

Ua paʻa paha ka mokuʻāina i pelu ʻia a hui ʻia?

ʻŌiwi MS, CD, DSC

E heluhelu i ka papaʻaina e like me nā laina kikoʻī ʻehiku, aole hookahi helu maemae. ʻO kahi palapala hōʻike e hōʻike ana i ka lālani ʻelua wale nō i haʻi iā ʻoe e pili ana i ka pane ʻike a ʻaʻohe mea e pili ana i nā ʻeono ʻē aʻe.

Nā Metric Proteoform no ka Hoʻohālikelike Peptide: Ma waho aʻe o ke Kaʻina Maʻemaʻe

No ke aha ʻaʻole lawa ka ʻike kikoʻī o ka Sequence Identity wale nō

He kūlana hoʻomaka ka ʻike sequence, ʻaʻole kahi kikoʻī hoʻokuʻu, no ka mea, he mau kuleana ʻokoʻa ka ʻike a me ka heterogeneity i loko o ke kaʻina hoʻoponopono. ʻO ka wehewehe ʻana o ICH Q6B o kahi kikoʻī he papa inoa o na hoao, kuhikuhi i nā kaʻina hana kālailai, a me nā ʻae ʻae i hōʻike ʻia ma ke ʻano he palena helu, nā pae a i ʻole nā ​​pae hoʻohālike ʻē aʻe. Manaʻo ka Q6B i ka heterogeneity, me nā hiʻohiʻona isoform, hoʻololi ma hope o ka unuhi ʻana, nā ʻāpana a me nā ʻāpana, e hoailonaia, akā, ʻaʻole ia e hana i ka dossier characterization i ka kikoʻī. Hoʻohana nā palapala ʻelua i nā kumu like ʻole, a ʻo ka mea hoʻolako i ka mea mua wale nō i hoʻolako i ka hapalua o ka pūʻolo.

ʻO nā koi ʻEulopa i kēia manawa e hōʻike maopopo i ka ʻaoʻao ʻike. ʻO ka EMA synthetic-peptide alakaʻi, i mana mai 1 Iune 2026, paipai ʻia ma ka liʻiliʻi ʻelua mau ala orthogonal no ka ʻike ʻana i ka wā e hoʻokuʻu ʻia ai a koi i ka hui pū ʻana e hōʻoia i ke kaʻina.. Aʻo pū ia i ka palapala peptide no nā peptides lōʻihi kahi e paʻakikī ai ke kaʻina hana MS / MS. Hoʻokahi nuipa paʻa, pololei nae, hoʻokahi ala.

Nā Metric Proteoform no ka Hoʻohālikelike Peptide: Ma waho aʻe o ke Kaʻina Maʻemaʻe

Lawe ka ʻaoʻao haumia i nā helu. Hoʻohana like ke alakaʻi i ka Ph. Eur. 2034 paepae: ʻO nā mea haumia pili peptide i hōʻike ʻia ma luna 0.1%, i ʻike ʻia ma luna 0.5% a kūpono ma luna 1.0%. No ka hana hoʻohālikelike e kūʻē i kahi huahana kuhikuhi olaola manaʻo ia i ka palena helu o 0.1% no ka ho'āʻo maʻemaʻe LC.

He mau nīnau hana like ʻole ka hōʻike ʻana i ka naʻau a me ka ʻike ʻana. ʻO kahi ala hiki ke hoʻohālikelike ma kahi kokoke i kahi paepae hōʻike e pono ai i nā hōʻike hoʻohui hoʻohui e ʻike ai i kahi haumia i ʻike ʻia.; ʻO ka hihia he uhi hōʻike, ʻaʻole ʻo ka paepae helu haʻahaʻa he emi ka koi.

Maemae, ʻEkolu Helu ʻokoʻa ka ʻike a me ka ʻike

Maemae, ʻO ka ʻike a me ka ʻike he ʻekolu ana ʻokoʻa, a ʻelua mau mea kūʻai aku 98% ʻAʻole hiki ke hoʻohālikelike ʻia nā helu ke ʻole e hōʻike ʻia nā mea ʻekolu i ke ʻano like. ʻO ka maʻemaʻe kahi pākēneka ʻāpana pili mai kahi ʻano chromatographic. ʻO ka ʻike he hōʻoia i kūkulu ʻia. He nui loa ka maʻiʻo. Hiki iā lākou ke neʻe kūʻokoʻa, a nui ka hiki 98% maʻemaʻe ma ka ʻāpana ʻoiai e lawe ana i ka peptide liʻiliʻi i kēlā me kēia vial ma mua o ka hōʻailona.

ʻO ka pākēneka ʻāpana ka helu hapa nui loa o nā ʻekolu. He lākiō ia o ka pane detector, no laila e pili ana i ka lōʻihi nalu, gradient, kolamu a me ka hoʻouka ʻana, ʻaʻohe mea e pili ana i ke ʻano o ka piko nui. ʻO ke aʻo ʻana i alakaʻi ʻia e NIST o nā ʻano helu helu peptide i maʻalahi ke kumu kumu: ʻAʻole ʻae nā ala hoʻohālikelike like ʻole i hoʻohana ʻia i ka mea peptide like, ʻo ia ke kumu e pono ai ka ʻike i kahi ala paʻa e like me ka loiloi amino acid, qNMR a i ʻole ke kaulike nui ma mua o kahi chromatogram.

E hoʻopaʻa i ka hoʻomanawanui nui mai ka hana mea kani, hoʻolālikelike, olelo hooholo, ka hoʻopaʻa ʻana i ka mokuʻāina a me ka koi ʻike i manaʻo ʻia. ʻAʻole i hoʻokumu ʻia ka hoʻomanawanui ʻana ma waena o ± 0.05% ma aneʻi; ʻAʻole hiki i kahi pāʻani lehulehu wale ke hoʻoholo i nā kaʻina a i ʻole nā ​​​​mea koho stereochemical.

ʻŌlelo aʻo: Wahi % ʻaʻole ʻoluʻolu, a ʻaʻole ʻike ka ʻike. E noi i nā mea ʻekolu, a i ʻole e haʻi pololei i ka mea āu e ʻae nei.

ʻO ka hopena kūpono he nīnau e waiho ai i kekahi mea hoʻolako: ʻo wai o kēia mau helu ʻekolu ma ka palapala, ma ke ala hea, a kūʻē i ke kūlana kuhikuhi? ʻAʻole hiki i ka mea hoʻolako ke hoʻokaʻawale i nā mea ʻekolu i ke kamaʻilio ʻana ʻaʻole paha i hoʻokaʻawale iā lākou i loko o ka pūʻolo data.

Nā hoʻololi a me nā ʻoki ʻana ma hope o ka unuhi ʻana: He aha ka hōʻikeʻikeʻikepili

ʻAʻole manaʻo koʻikoʻi ka ʻoki ʻana, akā ʻo nā helu prevalence i paʻi ʻia mai ka noiʻi proteomics a pono e heluhelu ʻia pēlā. A 2025 meta-analysis o 50 nā ʻikepili luna-lalo uhi ʻoi aku ma mua o 140,000 proteoforms mai kahi 14,500 Ua ʻike ʻia nā proteins ma kahi kokoke 71% o nā proteoforms i hōʻike ʻia ua ʻoki ʻia a pili 29 ± 3% he lōʻihi piha. Hōʻike ʻia kēlā mau proteoforms i nā haʻawina i paʻi ʻia, ʻaʻole ke ʻano o nā peptide i hana ʻia, a he mea koʻikoʻi ka ʻokoʻa no kēlā me kēia mea e hōʻike ana i kahi hōʻike hoʻokuʻu.

Kahi e noho ai nā Proteoforms i hōʻike ʻia Hana ʻia nā proteoform lōʻihi piha 29% o nā proteoforms i hōʻike ʻia, N-terminal-wale nō ʻoki ʻoki 28%, ʻoki ʻelua-termini 26% a me nā ʻoki C-terminal-wale nō 17%. Kahi e noho ai nā Proteoforms i hōʻike ʻia. ʻikepili donut: piha piha 29; N-terminal wale nō 28; C-terminal wale nō 17; 26. Source: Waiwai, Ke kumu, a me ka kūlike o nā mea hoʻoponopono i ʻoki ʻia ma nā haʻawina hoʻopaʻa ʻia ma luna o lalo 2025-11-12. Kahi e noho ai nā Proteoforms i hōʻike ʻia 100 huina Loaʻa piha 29 N-terminal wale nō 28 C-terminal wale nō 17 ʻO ka hope ʻelua 26 Puna: Waiwai, Ke kumu, a me ka kūlike o nā mea hoʻoponopono i ʻoki ʻia ma nā haʻawina hoʻopaʻa ʻia ma luna o lalo (2025-11-12)

Iloko o ka heluna kanaka i okiia, ʻaʻole pololei ke kuhikuhi. ʻO ka like meta-analysis nā hōʻike 28 ± 1% ʻoki wale ʻia ka N-terminally, 17 ± 1% ʻoki wale ʻia C-terminally a 26 ± 3% ʻoki ʻia ma nā palena ʻelua. Ua lanakila ka poho N-terminal. Ua ʻike ʻia kahi haʻawina hoʻohaʻahaʻa hoʻohaʻahaʻa ʻokoʻa o ka liraglutide i ʻewalu mau mea haumia N-terminally oki ʻia., e hui ana ma ke ala like mai kahi kihi hoʻokolohua ʻokoʻa.

ʻAʻole ʻo ia hōʻailona ke ola kino. ʻO ka nā manaʻo kiʻi ponoʻī a nā mea kākau ʻano e pili ana 15% o ka hōʻike truncations i laʻana hoʻomākaukau a e pili ana 10% i ka waihona a i ʻole e ʻimi i nā mea waiwai, e haalele ana 75% mea olaola. Hōʻike maopopo nā mea kākau ʻaʻole hiki ke hāʻawi hilinaʻi ʻia ka ʻoki ʻana i kahi kumu kūlohelohe a i ʻole mai ka ʻike MS wale nō.. ʻElua mau ʻike hou aʻe e pili ana i ka heluhelu ʻana i kahi ʻaoʻao ʻoki: ka nui, ʻaʻole ka nui o ka protein, wānana i nā helu oki (R² = 0.39), a wale no 16 ± 2% o N-terminally truncated proteoforms ua palapala ʻia ma UniProt.

ʻO ka "pehea" no kahi papahana kahi hiʻohiʻona kikoʻī. ʻO kahi ʻoki C-terminal e hui pū ana me ka piko lōʻihi ma lalo o ke ʻano hoʻokuʻu e hele i kahi hoʻomaʻemaʻe pākēneka o ka wahi a hāʻule i kahi bioassay., a e nānā maʻemaʻe ka palapala hōʻoia ma waena. ʻO ia ke ʻano no ka nuipaʻa paʻa a i ʻole ka heluhelu ʻana i luna ma ka ʻaoʻao o ka chromatogram, a no ka ʻike ʻana i ka pau ʻana o kāu kaʻina e nalowale ana.

He aha nā Native Mass Spectrometry i hoʻohui - a ma hea e kū ai

Hoʻohui ʻia ka hiki ke ʻike i nā proteoform e hōʻole ana i nā kahe hana, a kū pono ia i kahi ho'āʻo hoʻokuʻu kū kaʻawale. ʻO ka wehewehe ʻana o Leney lāua ʻo Heck i ke ʻano o ka "maoli". wehewehe i ka ʻenehana ma ka mālama ʻana i ke ʻano quaternary noncovalent, ʻo ia ka ʻōlelo e pili ana i ka mea i mālama ʻia i ka pae kinoea, ʻaʻole ia he ʻōlelo e pani ana ke ana i ka maʻemaʻe chromatographic.

ʻO ka mea e hoʻihoʻi mai hiki ke nui. A 2025 ʻo ka haʻawina ʻōiwi ma luna o lalo i hoʻihoʻi i nā hoʻololi ʻana i hala ʻole ka nānā ʻana maʻamau loaʻa ka ACE2 intact mass e noho ana 820 Da ma lalo o ka manaʻo ma hope o ka helu glycan, a me ka hana ʻāpana kūloko i hāpai i ka uhi ʻana mai 10.6% i 30.9%. Ma ka haʻawina hoʻokahi, Ua hōʻike ʻo SPP1 i ʻelua mau ʻoki C-terminal ma ka ʻaoʻao o kahi kikowaena C i hana ʻole ʻia, me ka lōʻihi piha ka mea nui. ʻO ia nā ʻano o nā ʻano mea hiki ke nalo loa i ke kaʻina hana ma lalo iho wale nō.

Ua like nā palena. Pono nā kūlana kūlohelohe e hoʻololi i ka paʻakai paʻakai e like me ka ammonium acetate, a me ke koena nonvolatile e hoʻohui i nā proteins, ka hoʻonui ʻana i nā piko a me ka hoʻohaʻahaʻa ʻana i ka hoʻonā nuipa. ʻAʻole hiki i nā paepae ke hoʻonā i nā hui like ʻole me nā ʻokoʻa liʻiliʻi, me nā PTM hoʻokahi a me nā hoʻohui ligand liʻiliʻi. A paʻi ʻia ke kuʻuna kulanui kau i ka laulā hana kūpono ma 1 i 25 µM protein i loko 50 i 200 mM aqueous ammonium acetate, me 100 mM he paʻamau maʻamau.

E mālama i ka MS maoli ma ke ʻano he ʻenehana orthogonal i loko o kahi pūʻolo. Inā hoʻohana ʻia ma ke ʻano he ʻano hoʻomalu ma mua o kahi mea hana kikoʻī, pono ia e hōʻoia i kāna kumu i manaʻo ʻia ma lalo I Q2(R2), aponoia i Nowemapa 2023, me ka kikoo, laula, pololei, pololei a me nā palena i wehewehe ʻia no ia hoʻohana. ʻAʻole ia i manaʻo ʻia ma ke ʻano he hana compendial, ʻaʻole pono e hoʻomaopopo kekahi.

Heluhelu i kahi CoA Kūikawā Nui: He aha ka mea e pono ai ma laila a me ka mea pono ʻole

E wehewehe i nā hōʻike e like me ka hoʻohana i manaʻo ʻia. ʻO kahi paʻa 95% a i ʻole 99% ʻAʻole hoʻokumu ka pae hoʻomaʻemaʻe wahi i ka kūpono no nā noiʻi āpau, nā haʻawina lāʻau lapaʻau a i ʻole mechanistic. Pono nā māla i nalowale i nā nīnau i manaʻo ʻia ma mua o nā manaʻo e pili ana i ka hoʻāʻo ʻana o ka mea hoʻolako i ka hailona.

Kahua

Pehea ke ʻano o ke komo piha ʻana

He aha kona nele e haʻi iā ʻoe

Pili ka nui

Kou helu hailona, hana ʻana Mea hoʻolako Rpeptide a hoʻāʻo hou i nā lā

He mea maʻamau nā palapala hōʻoia "Sample" a i ʻole "maʻamau" i waena o nā mea hoʻolako i hoʻāʻo ʻole i kēlā me kēia pūʻulu

Maemae

Wahi HPLC % me ke kolamu, kaʻina lawe lima, gradient a me ka lōʻihi nalu

ʻAʻole nā ​​kikoʻī o ke ala i kaupalena ʻia ka wehewehe ʻana; noi i ka moʻolelo kākoʻo

ʻIkepili

Nānā ʻia versus theoretical mass, me ke ʻano MS i ʻōlelo ʻia

ʻO ka maʻemaʻe HPLC me ka ʻole o ka ʻikepili MS e waiho i ka ʻike i hōʻoia ʻole ʻia, no laila e mālama i ke kiʻi maʻemaʻe me ka kānalua M Peptides kuai nui

ʻaelike lehulehu

ʻIke ʻia ʻo MW i loko o kahi ʻae ʻia o ka manaʻo

He kūlike ʻole, a i ʻole ʻaʻole i ʻōlelo ʻia ke ahonui, 'o ia ho'i, 'a'ole i hō'oia 'ia ka piko mua ma ke 'ano he pahuhopu

palapala ʻāina haumia

Kapa ʻia a hōʻike ʻia paha nā piko, me nā piko i ʻike ʻole ʻia i wehewehe ʻia

ʻO nā piko nui i ʻike ʻole ʻia i ka chromatogram he hae ʻulaʻula iā lākou iho Dynorphin

Huina

ʻO nā lakio amino acid e kūlike me ke kaʻina i manaʻo ʻia

Hōʻike nā ratio like ʻole i kahi kaʻina a i ʻole pilikia hoʻohui

Hoʻāʻo ʻaoʻao ʻekolu

He inoa, hale hana ʻae ʻia

ʻAʻole hiki ke hōʻoia ʻia kahi "lawe ʻaoʻao ʻekolu" ma ka hoʻolālā ʻana, a ʻoi aku ka maikaʻi o ka hoʻāʻo ʻana i loko o ka hale ma ke ʻano he hōʻoia kūʻokoʻa

Endotoxin

Ka hopena inā hoʻāʻo ʻia, me ke ʻano

Nalo kahi e pono ai ka palapala noi, ʻaʻole kahi hala

Nā Paepae Hoʻomaʻemaʻe Synthetic-Peptide Nā Paepae Hoʻomaʻemaʻe Synthetic-Peptide: waiwai no ka Hoike, E hoomaopopo, Kupono. Nā Paepae Hoʻomaʻemaʻe Synthetic-Peptide. ʻikepili pae pae: Hōʻike 0.1; E hoomaopopo 0.5; Pono 1.Source: EMA Alakaʻi no ka hoʻomohala ʻana a me ka hana ʻana o nā Peptides Synthetic 2026-06-01. Nā Paepae Hoʻomaʻemaʻe Synthetic-Peptide Hōʻike 0.1 E hoomaopopo 0.5 Kupono 1 Puna: EMA Alakaʻi no ka hoʻomohala ʻana a me ka hana ʻana o nā Peptides Synthetic (2026-06-01)

ʻO ka helu o ke kaʻina hana ʻo ia ka hanai ʻana o kēia pepa hana i mua. Lilo nā māla like i ka protocol comparability ke hoʻololi ke kaʻina hana, a kākoʻo ka hōʻike like i ka hoʻouna ʻana i ka IND. ʻAʻole hiki i kahi CoA ke ola i kēia papa ʻaina ʻaʻole e ola i kahi hana hoʻohālikelike.

E wehewehe ana i ka hohonu o ke ano: He lula hoʻoholo ma ka pae hoʻomohala

Pono ka hohonu o ka wehewehe ʻana me ke kumu kūʻai o ka pane hewa, ʻaʻole me ka uku o ka palapala hōʻoia. He maʻalahi ka lula hoʻoholo: E wehewehe i nā ʻano i hoʻololi ʻia i kahi hoʻoholo āu e hana ai, a kū i laila. ʻO nā mea ʻē aʻe he characterization hiki iā ʻoe ke paʻa i kahi mālama.

Ke kahua

He aha kāu e hoʻoholo nei

pūʻolo liʻiliʻi

Hoʻohui i ka wā

ʻO ka hiki a me ka nānā ʻana

He kūpono ke hahai ʻana i ke kaʻina

HPLC maemae, ka ʻike MS paʻa

He lōʻihi ke kaʻina, hydrophobic a i ʻole cysteine-waiwai

ʻO ke alakaʻi maikaʻi

ʻO ka ʻano like ʻole e lawe i mua

Maluna, me ka palapala peptide LC-MS/MS

ʻOkoʻa nā ʻano like ʻole e kahi PTM a i ʻole koena hope

Preclinical a me IND-hiki

Inā mālama ʻia ke kaʻina hana

Maluna, me ka ʻike pūnaewele, palapala ʻāina haumia, hoʻohaʻahaʻa ikaika

Ka pilikia o ka immunogenicity, ʻano haumia hou, ka hoʻohālikelike ʻana i kahi huahana kuhikuhi

Kalepa a me ke ola

Inā noho like nā hailona

Nā kikoʻī piha no ICH Q6B, nā ʻano i hoʻopaʻa ʻia i kēlā me kēia Q2(R2)

Hoʻololi ke ʻano, hoʻololi mea hoʻolako, hoʻololi pālākiō

Noho ʻelua lula ma lalo o ka papaʻaina. Ka mua, ka hohonu o ke kahua, ʻoi aku ka maikaʻi o ka pale ʻana ma mua o ka ʻike wale nō: kūlana hōʻoia, hoʻomaka ka pono o ka ʻikepili a me ka traceability e like me ke ana. Ka lua, ʻO ka paʻakikī ke koho i ke ʻano ma mua o ka hana ʻana. Nā peptide lōʻihi, nā paʻa disulfide lehulehu, hydrophobic kikoo, ʻO nā kaʻina aggregation-prone a me cyclic a stapled structures nā hihia a pau kahi helu maʻemaʻe HPLC hoʻokahi i kaupalena ʻia., a ma kahi e hoʻonoho ʻia ai nā pae hoʻohālikelike me ka manaʻo o ke ʻano ma mua o ka paepae maʻamau.

ʻO kēia kahi e lilo ai ka mea hoʻolako i nīnau kikoʻī ma mua o kahi kūʻai. Mālama ʻo MOL Changes i nā kaʻina a hiki i 120 nā ʻakika amino, nā disulfides lehulehu, hydrophobic a me ka hoʻohui ʻana, a me nā peptides cyclic a stapled, a hāʻawi i nā hoʻololi e pili ana i ka phosphorylation, hoʻohāhā, glycosylation, lipidation, PEGylation a me ka laulā o nā lepili fluorescent. No kahi papahana ma ke kahua preclinical, ʻO ka hoʻāʻo kūpono inā hiki i ka mea hoʻolako ke hāʻawi i nā koina ʻae e kūlike i nā palena o ke ʻano no kēlā kaʻina kikoʻī, a hiki ke lawe i ka pūʻolo like mai ka milligrams a i ka grams me ka hoʻololi ʻole i ka wehewehe o ka hailona.

ʻO nā manaʻo kuhihewa maʻamau e kūʻai ana i ke kumukūʻai

ʻO ke kolu, he pilikia ka ʻoki ʻana i nā molekole o nā poʻe ʻē aʻe. Hōʻike ka ʻike liraglutide i ka hoʻohaʻahaʻa ʻana i ka N-terminal ma ke ʻano he ala haumia nui no kahi peptide kūʻai., a ʻo ka ʻikepili proteomics e hōʻike ana i ka ʻaoʻao hoʻokahi e noho aliʻi ana ma nā ʻikepili nui. ʻAʻole hoʻi e haʻi iā ʻoe ua ʻoki ʻia kāu ʻāpana. Hōʻike ʻia nā mea ʻelua iā ʻoe he pono ka hoʻāʻo ʻana i hoʻokahi hoʻokolohua nui ma mua o kou manaʻo ʻana.

ʻO ka hā, ʻo ka CoA piha ke nānā aku he pūʻolo piha. ʻO nā hae ʻulaʻula ke kūkulu, ʻaʻole hoʻonaninani: ʻaʻohe kumu, hale hana i kapa ʻole ʻia, hōʻike ʻia i loko o ka hale ma ke ʻano he hōʻoia kūʻokoʻa, a me ka maʻemaʻe i hōʻike ʻole ʻia me ka ʻike ʻole. Hiki ke lōʻihi ka palapala hōʻoia, hoʻopili ʻia a hāʻule mau i kēlā me kēia o kēlā mau loiloi.

Nīnau pinepine

He aha ka ʻokoʻa ma waena o ka maʻemaʻe peptide a me ka ʻike peptide?

Hōʻike ka hoʻomaʻemaʻe ʻāpana Chromatographic i kahi hopena kiʻekiʻe i wehewehe ʻia; ʻike ʻike i ka ʻano molekala. ʻAʻole hōʻike ʻia kahi waiwai wahi kiʻekiʻe. Manaʻo ʻo EMA i nā ala ʻike hoʻohui no ka hoʻokuʻu ʻana i ka synthetic-peptide lāʻau lapaʻau; ʻAʻole kēlā manaʻo he pae hoʻomaʻemaʻe noiʻi honua.

ʻO nā metric proteoform pili i nā peptides synthetic, aiʻole i nā mea olaola wale nō?

Pili lākou i kēlā me kēia peptide i hiki ke loaʻa i ka nui o nā ʻano molecular, ʻo ia ka peptides synthetic me ka oxidized, ʻano ʻano ʻoki ʻia a ʻoki ʻia paha. Pili pololei nā paepae haumia o ke alakaʻi alakaʻi EMA a me kāna ʻōlelo aʻo e pili ana i ka hui ʻana i nā haumia. Nā helu prevalence proteomics, ma ke ʻano like ʻole, wehewehe i ka ʻikepili noiʻi a ʻaʻole pono e heluhelu ʻia ma ke ʻano he haku mele.

Hiki ke hoʻololi i ka HPLC no ka hoʻokuʻu ʻana i ka spectrometry?

ʻAʻole. ʻO ka MS maoli ka palena palena, pono i nā paʻakai volatile e like me ka ammonium acetate, a pinepine ʻaʻole hiki ke hoʻoholo i nā ʻokoʻa liʻiliʻi liʻiliʻi. Hoʻohana maikaʻi ʻia ma ke ʻano he ʻenehana hōʻailona orthogonal, a inā hoʻohana ʻia ʻo ia ma ke ʻano he mana hoʻomalu pono e hōʻoia ʻia i kēlā kumu ma lalo o ICH Q2(R2).

ʻEhia ka nui o ke ʻano e pono ai i kahi pūʻolo peptide preclinical?

Ma ka liʻiliʻi, ʻike ʻike ma nā ʻano orthogonal ʻelua, maʻemaʻe me ke ʻano i ʻōlelo ʻia a me ka palena helu, maʻiʻo ʻupena ma ke ʻano holoʻokoʻa, a me kahi palapala ʻāina haumia e hōʻike ana i nā piko i ʻike ʻia. Hoʻohui i ka hoʻohaʻahaʻa ikaika a me kahi ʻaoʻao o ka ʻoki ʻana kahi e pono ai ke kaʻina a i ʻole ka pilikia immunogenicity.

Ka hopena: Ke hoʻololi nei i nā Metric Proteoform i kahi kikoʻī hiki iā ʻoe ke pale aku

ʻO ka mea e lawe ai ʻo ia kahi kikoʻī peptide e wehewehe i kahi heluna kanaka, ʻaʻole he kaʻina. ʻIkepili, ka maemae, maʻiʻo, hōʻike hoʻololi, ʻaoʻao ʻoki, ʻO ka heterogeneity a me ka conformationally pili nā ʻano ʻano ʻokoʻa, a pono kēlā me kēia i kahi ala, he palena a he kumu no ka noho ana. ʻO ka hoʻoholo hoʻoholo peptide characterization e hahai mai kēlā: E wehewehe i ka mea e hoʻololi ai i kāu hoʻoholo e hiki mai ana, hōʻoia i ka mea āu i kuhikuhi ai he mana, a mālama i ke koena ma ke ʻano he hōʻailona hiki iā ʻoe ke huki i ka wā e kū mai ai kahi nīnau.

He pōkole ka papa inoa e haʻalele ai. E hōʻoia i ʻelua ʻano hana ʻike orthogonal. E hoʻokaʻawale i ka maʻemaʻe mai ka ʻike a noi i nā mea ʻelua. E nīnau i ka palena ʻoi loa ka pilikia no kāu kaʻina a inā e ʻike ʻia ke ʻano hoʻokuʻu. E heluhelu i ka CoA e pili ana i ka pepa hana ma luna, kahua ma ke kahua. E hoʻohālikelike i ka pūʻolo i ka pae hoʻomohala ma mua o kahi hoʻohālike. A inā ʻaʻole hiki i ka mea hoʻolako ke pane i kahi nīnau e pili ana i ke ʻano a i ʻole ka palena, e mālama i kēlā me ka ʻikepili e pili ana i ka pūʻolo.

Inā ʻoe e kuhikuhi nei i kahi polokalamu peptide a i ʻole enzyme a makemake ʻoe i ka pūʻolo kikoʻī i kūkulu ʻia a puni kāu kaʻina a me ke kahua, hiki i kā mākou hui ʻenehana ke hana ma o nā koi me ʻoe. Hāʻawi ʻo MOL Changes i ka peptide synthesis a me nā lawelawe kikoʻī; He hoʻonaʻauao kēia ʻatikala a ʻaʻole ia he ʻōlelo aʻoaʻo hoʻoponopono a lapaʻau paha.

Hōʻike ka mea hoʻopuka: Hāʻawi ʻo MOL Changes i nā lawelawe peptide a he hoihoi koʻikoʻi i kēia kumuhana. ʻO nā lālā lawelawe a me nā ʻōlelo hiki ke koi i nā mea hoʻolako; ʻO ka loaʻa a me ka hana ʻana no kahi kūkulu kikoʻī e koi i nā hōʻike kikoʻī o ka papahana.

Zejun Peng

Zejun Peng

Luna ʻenehana Nui; ʻO ka mea akamai i ka peptide Synthesis Kaʻike kumu: ʻO ka peptide synthesis paʻakikī, nā hoʻololi ʻana o ka amino acid kūlohelohe, a me ke kūkulu ʻana i nā peptides cyclic a me nā peptides stapled.

moʻokalaleo:He ʻike nui ʻo Zejun Peng i ka kemika kūlohelohe a me ka synthesis peptide. Maikaʻi ʻo ia i ka hoʻohana ʻana o ka solid-phase peptide synthesis (SPSS) a me ka peptide synthesis wai (LPPS), a akamai loa i ka lanakila ʻana i nā "paʻakikī loa-e-synthesize sequences" (e like me nā peptides ultra-long-chain, nā kaʻina hydrophobic kiʻekiʻe, a me ka pelu ana i na mea paa disulfide lehulehu). Ma lalo o kāna alakaʻi, ua lanakila ka hui i nā bottlenecks ʻenehana i kekahi mau hoʻololi kūikawā (e like me ka N-methylation, PEGylation, a me ka lepili fluorescent), ka mālama ʻana i ka helu kūleʻa synthesis o luna 98%.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana